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Fragile X syndrome (FXS), the most common inherited cause of intellectual disability,
learning disability, and autism spectrum disorder, is associated with an increased
prevalence of certain medical conditions including seizures. The goal of this study was to
better understand seizures in individuals with FXS using the Fragile X Online Registry with
Accessible Research Database, a multisite observational study initiated in 2012 involving
FXS clinics in the Fragile X Clinic and Research Consortium. Seizure data were available
for 1,607 participants, mostly male (77%) and white (74.5%). The overall prevalence of at
least one seizure was 12%, with this rate being significantly higher in males than females
(13.7 vs. 6.2%, p < 0.001). As compared to individuals with FXS without seizures, those
with seizures were more likely to have autism spectrum disorder, current sleep apnea,
later acquisition of expressive language, more severe intellectual disability, hyperactivity,
irritability, and stereotyped movements. The mean age of seizure onset was 6.4 (SD
6.1) years of age with the great majority (>80%) having onset of seizures which was
before 10. For those with epilepsy, about half (52%) had seizures for more than 3
years. This group was found to have greater cognitive and language impairment, but not
behavioral disruptions, compared with those with seizures for < 3 years. Antiepileptic
drugs were more often used in males (60.6%) than females (34.8%), and females more
often required more than one medication. The most commonly used anticonvulsants
were oxcarbazepine, valproic acid, lamotrigine, and levetiracetam. The current study
is the largest and first longitudinal study ever conducted to describe seizures in FXS.
Overall, this study confirms previous reports of seizures in FXS and extends previous
findings by further defining the cognitive and behavioral phenotype of those with epilepsy
in FXS. Future studies should further investigate the natural history of seizures in FXS and
the characteristics of seizures in FXS in adulthood.
Keywords: Fragile X syndrome, seizures, epilepsy, longitudinal, autism spectrum disorder
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INTRODUCTION

Studies investigating the association of seizures with other
disease features in FXS include a small cohort which showed a
trend toward an increased rate of seizures in individuals who
were also diagnosed with ASD (26) and a second small case
series of 11 patients which suggested an association between
epilepsy and attention problems (27). In the largest investigation
of seizures in FXS involving 1,394 individuals assessed by a
survey and 352 individuals assessed in clinic (19), 14% of males
and 6% of females reported seizures. Seizures tended to be
infrequent and more often focal, had onset between 4 and 10
years of age, were generally easily treated, and were associated
with ASD, but not academic achievement. A clinic-based study
of 135 patients with FXS seen in clinic (17) suggested that many
patients described spells such as staring, but most of these were
without EEG correlate, and only 4.4% of the cohort were actually
diagnosed with seizures, emphasizing the importance of clinical
confirmation of seizure diagnoses in persons with FXS. A large
study of ASD in FXS based on data from 547 participants with
FXS in the Fragile X Online Registry and Accessible Research
Database (FORWARD) natural history study (28) showed that
having a diagnosis of ASD was associated with an approximately
three-fold increased risk of seizures both in younger children and
in adolescent/young adults (29).
The Fragile X Clinic and Research Consortium (FXCRC)
initial database collected data from 260 participants with FXS
from 9 FXS Clinics from 2005 to 2011 and showed a seizure
frequency of 10% (12% in males) (2). Longitudinal data about
seizures from participants with FXS have subsequently been
collected as part of the FORWARD project (28), from 2012
to 2021. In the present report, we use these FORWARD data
to investigate seizure prevalence and characteristics, including
gender differences, age of onset and resolution, duration and
associated comorbid conditions, and other features (e.g., use of
anticonvulsants), in the largest and first longitudinal study ever
conducted to describe seizures in FXS. Specific goals of these
analyses are to update information on seizure frequency and cooccurring problems associated with seizures in FXS in a larger
group than previously reported, study the onset and trajectory
of seizures experienced by those with FXS across time with
longitudinal data, and understand factors associated with more
severe epilepsy in FXS.

Fragile X syndrome (FXS) is the most common known
inherited cause of intellectual disability, learning disability,
and autism spectrum disorder (ASD), with an estimated
prevalence of about 1/4,000 (1). Individuals with FXS
display variable physical features such as large ears, long
face, macrocephaly, macroorchidism, and variable levels of
functioning, with a fairly stereotyped cognitive profile and
behavioral features characterized by hyperactivity, anxiety,
and socialization difficulties. Additionally, certain medical
problems are more common in FXS, such as strabismus, otitis
media, gastroesophageal reflux, loose stools, sleep apnea, and
seizures (2).
FXS results from a trinucleotide repeat (CGG) expansion
mutation of >200 repeats (full mutation) in the promoter of
FMR1 (fragile X mental retardation 1) gene (3) which leads
to transcriptional silencing of FMR1 and loss or significant
reduction of expression of the gene product, FMRP (fragile
X mental retardation protein) (4). FMRP is an RNA-binding
protein that appears to function as a dendritic translational
repressor that modulates receptor-activated dendritic protein
synthesis and regulates multiple ion channels (5–7). In the
absence of FMRP in the Fmr1 knockout (k/o) mouse model of
FXS, there is immature dendritic spine morphology and regionand cell-dependent deficits in synaptic plasticity (8). Accordingly,
these synaptic abnormalities result in abnormal epileptiform
discharges (9) and a high frequency of audiogenic seizures in the
Fmr1 k/o mouse (10), presumably modeling the increased risk of
seizures in humans with FXS.
Past reports have identified seizures in 4.4%-40% of males
with FXS (2, 11–19) with a lower frequency of 4.4%-18% in
larger cohorts with less referral bias (2, 13, 15–19). Many
children with FXS also have abnormal electroencephalograms
(EEGs) without overt epileptic seizures (15, 17, 19), frequently
with a pattern of centrotemporal spikes (similar to benign
focal epilepsy of childhood) (13, 15, 19, 20). Types of seizures
reported in FXS vary widely, and clinical and EEG findings
consistent with Panayiotopoulos syndrome, a benign autonomic
epilepsy syndrome, have also been seen in FXS (21). Complex
partial (focal onset with impaired awareness) seizures were
reported as most common in FXS in several series (13, 15, 18),
although simple partial (focal onset without impaired awareness)
and generalized tonic-clonic seizures occur often, and status
epilepticus has also been observed (22). Seizures are reported to
be easily controlled in most cases (15, 17, 18) and resolve during
childhood in the majority of individuals with FXS, although in
a study of hospital encounters for adolescents and adults with
FXS, seizures represented an identifiable reason for emergency
room presentation and hospitalization in FXS (23). Occasional
patients with FXS and intractable seizures due to mesial temporal
sclerosis have been described, suggesting a secondary etiology
amenable to surgical management (24). A small case series
describing three females with FXS and severe developmental
impairment and medically refractory focal epilepsy also suggests
that severe epilepsy in FXS may signal a secondary genetic
condition (25).
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MATERIALS AND METHODS
Data analyzed for this report were derived from FORWARD.
As described previously (28), FORWARD is a multisite
observational study initiated in 2012. The study collects data
yearly on a Registry form, Parent Report form, and Clinician
Report form, as well as standardized questionnaires including
the Aberrant Behavior Checklist-Community Edition (ABCC) (29), the Social Communication Questionnaire (SCQ) (30),
and the Social Responsiveness Scale – Second Edition (SRS2) (31). The analyses for this report were performed using
baseline and longitudinal data collected during follow-up visits
from FORWARD Version 5, with data obtained from 1,607
individuals with FXS evaluated between 2012 and 2020, who had
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information available about seizures derived from the Clinician
Report form. There were 1,607 baseline visits and 1,945 followup visits (occurring after the baseline visit) for 803 participants
with at least 1 year of follow-up. The study was approved by
the Institutional Review Board for each participating FXS Clinic
where data were collected, and written informed consent was
obtained from primary caregivers or adult patients who were
their own guardians.
Demographic variables including age, sex, and ethnicity were
collected on the Registry form. Data from the Clinician Report
form included variables related to seizures including presence
or absence of seizures currently or in the past, age (in years
and months) at seizure onset, age when seizures resolved if the
participant had been 2 years without seizures, type of seizures
(focal, generalized, febrile), whether antiepileptic medication
was used for seizures at the time of the visit, and, if so,
which antiepileptic medication(s) the participant was taking.
Antiepileptic medication use was tracked at all visits and was
reported in this paper based on use described at any visit over the
course of follow-up. Other data from the Clinician Report form
about problems that could potentially be associated with seizures
were also utilized, including level of intellectual disability (ID),
presence of ASD, presence of sleep apnea, severity of behaviors
on the ABC-C adjusted for FXS (ABCFX ) (32), and severity of
ASD symptoms on the SCQ and SRS-2.

TABLE 1 | Demographics of the FORWARD cohort.
Characteristic (N)*
Sex (N = 1607)

77% male

Race/ethnicity (N = 1607)

74.5% White, 7.7% African American,
3.4% Asian, 12.9% Hispanic, 1.4% Other

Age at first visit (years, N = 1607)

26.3% age 0–5, 27.1% age 6–10, 21.0%
age 11–15, 11.4% age 16–20, 14.2% age
21+

Number of visits (N = 1607)

1–804, 2–329, 3–191, 4–103, 5–73, 6–39,
7–39, 8–28, 9–1

ASD by clinician (DSM5, N = 1592)

39.5%

ASD by SCQ (N = 1187)

61% no ASD, 39% ASD

ASD by SRS (N = 1061)

16% no ASD, 42% mild ASD, 42% severe
ASD

Intellectual disability (N = 1536)

7.7% normal, 15.4% DD, 7.4% borderline,
23.2% mild, 38.7% mod, 7.2% severe,
0.3% profound

Current or past seizures (N = 1607)

12%

Current or past sleep apnea
(N = 1323)

16.9%

*N is less than total based on missing data for some items, and the SCQ and SRS were
filled out separately from the Clinician forms and not collected on all individuals.

RESULTS
STATISTICAL ANALYSIS

Characteristics of the 1,607 FORWARD participants with
available seizure data used for this study are shown in
Table 1: 77% were male, 74.5% were White, 7.7% were African
American/Black, 3.4% were Asian, and 12.9% were Hispanic.
The mean age at the baseline evaluation for the cohort was 13.8
years. A history of current or past seizures at any evaluation
was reported for 193 patients (170 males and 23 females) or
12% of the sample. Approximately half had moderate (38.7%) or
severe/profound (7.5%) ID, ∼39.5% were diagnosed with ASD by
a clinician, and sleep apnea was present in 16.9% of the cohort.
Severity of ID, ASD symptom severity by SRS-2, and percent of
patients with an ASD diagnosis by SCQ were all lower in females
with FXS relative to males.
In the entire cohort, there were a higher proportion of males
with FXS relative to females who had current or past seizures at
any time prior to baseline or during follow-up, 13.7 and 6.2%,
respectively (Fisher’s exact p < 0.0001). Seizures occurred more
often in severely affected patients, with 68.7% of patients with
seizures having moderate, severe, or profound ID, while only
43% of patients without seizures had this level of ID (chi-square
p < 0.0001 for distribution of ID within the seizure and no
seizure groups, Table 2, Figure 1A). Those with seizures had
later onset of spoken language (age 2.37 vs. 2.02 years, ANOVA
p = 0.03). Those with seizures were more likely to have an
ASD diagnosis compared to those without seizures (53.9 vs.
41.9%, chi-square p < 0.0001, Table 2, Figure 1B). The group
with seizures had a trend to have an increased likelihood of
a diagnosis of ASD by SCQ (score of over 15) at the baseline
FORWARD visit (45.9 vs. 38.3%, Fisher’s exact p = 0.087),
although not statistically significant, and increased severity of

Frequency tabulations and proportions for categorical variables,
and means and standard deviations for continuous variables,
were used for the descriptive analyses. The chi-square test
or Fisher’s exact test for categorical variables, and analysis
of variance (ANOVA) for continuous variables were used to
compare characteristics of those with and without seizure
experience and to compare males and females with seizures.
Using longitudinal data, subjects were divided into three groups
based on seizure experience. Participants who reported no
seizures ever and who were observed at least once at or over the
age of 15 comprised one group; participants who reported having
seizures but only for a period <3 years and were followed at least
2 years after the last reported seizure comprised a second group;
and participants who reported seizures over a period >3 years
comprised the third group. Comparisons of demographic and
clinical variables between these three groups were made using
chi-square tests or Fisher’s exact tests, for categorical variables,
and Wilcoxon rank-sum test and Student’s t-tests for continuous
variables, as appropriate.
Kaplan–Meier survival estimates were produced to model and
plot time to first reported seizure for the full sample. Mixed-effect
logistic regression models were fit to estimate the rate of current
seizures for age groups, using the longitudinal data, across the full
sample. This model featured random intercepts for subject.
Analyses were performed using SPSS version 26 and SAS
version 9.4. In each analysis reported in this paper, data were used
for all individuals who had valid values for the variables used in
that analysis. Statistical significance level was set at 5%.
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Patients were more likely to have reported seizures if they
were older at the first and last evaluations (chi-square p < 0.0001
for age distribution between those with and without seizures),
thought likely to be related to being past the typical age of onset of
seizures in FXS. There was no effect of the number of evaluations
in FORWARD.
In the group of 193 patients with seizures (Table 3), the mean
age at the baseline visit was 13.7 ± 8.7 and the number of
evaluations during follow-up was 2.5 ± 1.8. The mean age of
seizure onset was 6.4 ± 6.1, and the mean time elapsed since
the last seizure was 6.4 ± 7.7 years. In most cases, seizure onset
occurred before the age of 10, including 86.7 and 81.8% of males
and females, respectively (Figure 2A). For males (N = 170), 96%
had the first seizure by age 15, with only 4% presenting after
age 15. For females (N = 23), 18.2% had their first seizure after
age 15, a trend in age distribution with borderline significance
(p = 0.058). The age of the last seizure followed a similar
distribution to age of onset of seizures with 70.9% and 63.6% of
seizures resolving by age 10 in males and females, respectively
(Figure 2B). Only 7.9% of males and 18.2% of females had
seizures continuing after age 20; this sex difference, based on a
low number of females, was not significant.
Partial seizures were reported in 25% and generalized seizures
in 31% of patients, with febrile seizures in 8% and the remainder
of seizures being of unknown type (Figure 3A). Males and
females did not show a different distribution of seizure types.
The average number of anticonvulsants used across the entire
group with seizures was 0.91 ± 1.01. Anticonvulsant use was
reported in 60.6% of males with seizures at any evaluation vs.
34.8% of females (Fisher’s exact p = 0.024, Figure 3B), with 37.6%
of males vs. 13.0% of females requiring a single medication (chisquare p = 0.035), and 23 and 22%, respectively, requiring two
or more medications. The most commonly used anticonvulsant
was oxcarbazepine, followed by valproic acid, lamotrigine, and
levetiracetam (Figure 3C).
During the follow-up period, 26 incident seizures were
reported in 20 males and 6 females in 1945 patient-years
of follow-up, for a calculated rate of 0.013 new seizures per
patient year of follow-up. Incident seizures had an age and
sex distribution resembling that for age and sex distribution of
seizures at baseline. Twelve males experienced a change in seizure
type in 283 patient years of follow-up, indicating that seizure
type changes about 4.2% of time in follow-up. Figure 4A shows
a Kaplan–Meier plot of age of seizure onset in the FXS cohort,
which reached a plateau by age 15 years. There was also an
apparent increase in seizure onset after age 25, despite the low
actual numbers of adults with seizures. This is most likely because
the Kaplan–Meier model estimated the proportion based only on
the subjects observed until later ages, even though many of the
younger subjects would have likely reached age 25 years without
having a seizure. For that reason, the Kaplan–Meier estimate of
the total proportion experiencing seizures (about 17%) is greater
than the raw calculation of the proportion reporting seizures
(12% as noted above). Figure 4B shows the proportion of patients
having seizures separated into 5 year groups. As expected, the
proportions are higher in the youngest groups, tapering off until
reaching the 26–30 year age group.

TABLE 2 | Association of cohort characteristics with seizures.
Characteristic

Seizures
(N = 193)

No seizures
(N = 1,414)

p-value**

N (% of total with seizures or no seizures)
Sex
Male
Female

<0.0001
170 (88.1)

1067 (75.4)

23 (11.9)

347 (24.6)

Age at first visit*

13.7 (8.7)

11.6 (9.4)

0.004

Age at last visit*

16.1 (8.9)

13.5 (9.8)

<0.00001

White non-Hispanic

139 (72.0)

1061 (75.0)

0.6

Black non-Hispanic

17 (8.8)

106 (7.5)

Race/ethnicity

Asian

9 (4.7)

45 (3.2)

24 (12.4)

184 (13.0)

4 (2.1)

18 (1.3)

No

80 (41.9)

847 (60.5)

Yes

103 (53.9)

526 (37.5)

No

80 (54.1)

641 (61.7)

Yes

68 (45.9)

398 (38.3)

8 (4.2)

28 (2)

Absence of ASD

12 (9.2)

153 (16.4)

Mild ASD

48 (36.9)

401 (43.1)

70 (48)

377 (40.5)

None

5 (2.7)

114 (3.0)

Devel Delay

11 (5.9)

226 (16.7)

Borderline

7 (3.8)

107 (7.9)

Mild

35 (18.8)

322 (23.9)

Moderate

102 (54.8)

493 (36.5)

Severe

25 (13.4)

85 (6.3)

1 (0.5)

3 (0.2)

7 (4.2)

29 (2.5)

Hispanic
Other
ASD diagnosis

<0.00001

ASD by SCQ

Unknown

0.087

ASD by SRS-2

Severe ASD

0.008

Level of ID

Profound

<0.00001

Sleep apnea
Currently
Past

0.001
7 (4.2)

69 (6.0)

No

130 (78.8)

1000 (86.4)

Don’t know

21 (12.7)

60 (5.2)

*Values reported are mean (SD). **Significance (p-value) is reported for distribution of
categories (chi-squared) in characteristic and indicates whether these are differently
distributed between the group with seizures and those without.

ASD symptoms by SRS-2 (9.2 vs. 16.4% absence of ASD, 53.8
vs. 40.5% severe ASD, chi-square p = 0.008). Current symptoms
of obstructive sleep apnea were seen more often in those with
seizures (4.2 vs. 2.5%) which led to a chi-square of p = 0.001
for the distribution of sleep apnea category between those with
and without seizures. However, if one considered past history of
sleep apnea, the distribution of seizures was similar in those with
and without sleep apnea, making it unclear whether there is a
true association. There were no effects of race/ethnicity, place of
residence, household income, or level of education of parents on
the likelihood of patients manifesting seizures at any time.
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FIGURE 1 | Association between intellectual disability (ID), autism spectrum disorder (ASD), and seizures in FXS. (A) The bar graph depicts the proportion (in
percentages) of individuals with and without seizures at each level of ID. Note the higher proportion of patients with seizures at the higher levels of ID severity. DD
corresponds to developmental delay in younger individuals. (B) The graph shows the proportion (in percentages) of individuals with and without seizures diagnosed (or
not) with ASD. Note in the group with ASD, a higher proportion of patients with seizures.

TABLE 3 | Characteristics of the FXS FORWARD participants with seizures.
# of
evaluations
(clinician form)

Age at first
evaluation

Age of
seizure
onset

SCQ Total
Score

Total SRS T
Scores

# of unique
medications
reported
across all visits

Years from last
seizure onset
to last
evaluation

Mean

2.48

13.39

6.22

16.17

76.12

0.95

6.42

N

170

170

150

131

114

170

151

SD

1.860

8.748

5.690

6.450

11.161

1.010

7.647

Mean

2.35

15.83

7.36

11.94*

75.69

0.61

6.23

23

23

22

17

16

23

22

SD

1.402

8.072

8.255

4.905

13.489

0.941

7.994

Mean

2.47

13.68

6.37

15.68

76.07

0.91

6.39

N

193

193

172

148

130

193

173

1.809

8.686

6.060

6.422

11.415

1.006

7.668

Sex

1 Male

2 Female

N
Total

SD

*p = 0.01, no other characteristics are significantly different between males and females.

Patients with persistent seizures, operationally defined as
those with seizures lasting over 3 years (N = 75), were compared
with those with seizures lasting <3 years (N = 70) and those
without seizures who had reached age 15 (N = 514) (Table 4).
The group without seizures was limited to those over 15 years
to ensure that the comparator group had a very low likelihood
of developing seizures. Those without seizures were older at the
first and last evaluation than the other groups; however, this
was expected given the age limitation on this group. There was
no significant difference in age at evaluation between the two
seizure groups. Relative to those with seizures <3 years, those
with seizures lasting >3 years were on more anticonvulsants (p
< 0.0001 both first and last evaluations), were more likely to
have partial seizures and less likely to have febrile seizures (p =
0.005 at first evaluation and 0.03 at last evaluation), made less

Frontiers in Pediatrics | www.frontiersin.org

language progress during follow-up, had more severe language
impairment at the most recent visit (p = 0.03), and had a
higher proportion of severe/profound ID (although this was
not statistically significant, p = 0.14), but did not have higher
prevalence of ASD, sleep apnea, or severity of behavioral issues
on any subscale of the ABCFX . The lack of language progress in
the group with seizures lasting >3 years was remarkable, with
25% non-verbal at the initial visit and 21.4% remaining nonverbal at the last visit compared to 14.4% non-verbal at the initial
visit and 5.7% at the last visit for those with seizures lasting <3
years. Underscoring the phenotypical severity associated with
having seizures regardless of duration, those with no seizures
had significantly less severe ID than the <3 year seizure group
(p = 0.003), less severe language impairment at the first but not
the last visit for those with seizures <3 years (p = 0.038 and
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FIGURE 2 | Age of onset and resolution of seizures. (A) Bar graph showing the proportion (in percentages) of individuals, divided by sex, with onset of seizures at
different 5 year bins. Note that, with exception of a subset of females with onset after age 15, most patients with FXS displayed an onset before age 10. (B) Bar graph
showing the proportion (in percentages) of individuals, divided by sex, experiencing last seizures at different 5 year bins. As for seizure onset, most patients had their
last seizure before age 15, with exception of a subset of females who has seizure resolution after this age.

FIGURE 3 | Seizure types and anticonvulsant use in FXS. (A) Pie graph depicting the proportion of each seizure type in the entire FXS cohort. (B) Graphs showing the
number of anticonvulsants per patient in males and females, respectively. Note the higher proportion of males on anticonvulsants. (C) Number of patients with FXS
using the most common anticonvulsants. Oxcarbazepine, valproic acid, and lamotrigine were the three most commonly prescribed anticonvulsants.
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FIGURE 4 | Plot of time to first seizure. (A) Reverse Kaplan–Meier estimates show the estimated proportion of subjects who had their first seizure onset reported, over
ages 0 to 30. Band shows 95% confidence intervals for estimates. For example, approximately 7% of subjects had first seizure onset by age 5, approximately 12% of
subjects had first seizure onset by age 10, and approximately 14% of subjects had first seizure onset by age 15. Bar chart of the model-estimated proportion of
having any seizures during selected age periods (B). Proportion estimates are derived from mixed-effect logistic regression models fit for the odds of having
experienced a seizure, with categorized age as the predictor, and random intercepts for subject.

greater overall cognitive and language impairments, but not more
severe behavioral problems.
In this FORWARD cohort, individuals with FXS and seizures
were more likely to have ASD diagnosed by the clinician based
on DSM5 criteria. The association between seizures and a clinical
diagnosis of ASD in children with FXS is supported by the
finding that this subset has more severe ASD symptoms on the
SCQ and SRS-2. Consistent with our findings, previous studies
have found an association between the diagnosis of ASD and
seizures and children with ASD with seizures have been found
to have more severe ASD symptoms (34, 35). However, although
previous studies suggested that children with ASD and genetic
disorders have high rates of epilepsy (36), this study suggests that
the rate of seizures in FXS is rather moderate, at 12%, comparable
to the 12.1% rate of epilepsy in individuals with idiopathic ASD
reported in a recent meta-analysis (37). Additionally, studies on
children with ASD also demonstrate that many have subclinical
epileptiform discharges in a centrotemporal pattern (38, 39) and
occipital regions (40), similar to EEG profiles reported in FXS
(13, 15, 19–21). Children with ASD and EEGs with subclinical
epileptiform discharges are found to be more severely impaired
(35, 41) but may show improvement in behavior and cognition
with treatments targeted to reduced epileptiform discharges (35,
38, 42). Although EEG data were not collected in the FORWARD
study, children with FXS and an abnormal EEG are a subgroup of
FXS patients that may warrant closer study.
Onset of seizures in FXS was typically (>80%) below age 10,
with a very low proportion of males having seizure onset after age
15 years. A higher percent of females had seizure onset after age
15 years, which suggests a slightly different pattern for seizure
onset in females, although females with first seizure at age >15
represented only four patients. Thus, the marginally significant
chi-square (p = 0.058) for a different male–female distribution of
age of seizure onset may be due to the relatively small number

0.15, respectively), less severe language impairment than those
with seizures >3 years at both visits (p = 0.0004 and 0.0062,
respectively), a higher percent with sustained conversation ability
at both visits than those with seizures <3 years at both visits (p
= 0.0003 and 0.01, respectively), a lower proportion with ASD
diagnosis than both seizure groups at both visits (p = 0.009 for
both groups at the last visit), and lower scores on the ABCFX
Hyperactivity, Irritability, and Stereotypy subscales than both
seizure groups at both visits (p-values ranging from <0.0001
to 0.029).

DISCUSSION
In this study, we characterized seizures in the largest clinically
evaluated cohort of individuals with FXS. In addition, this is
the only longitudinal study of seizures to date in FXS and
thus the only study ever to evaluate incident onset of seizures
prospectively in this syndrome. In addition to confirming
previously reported characteristics of individuals with FXS and
seizures, such as prevalence, sex distribution (13.7% males, 6.2%
females), and association with ASD (19, 26, 33), we identified
an association with current sleep apnea and additional features.
Those with seizures were also more likely to have more severe ID
and later onset of expressive language, findings which have not
been reported before, likely due to lack of sufficient numbers of
subjects (10–15, 26) or lack of clinical assessment or evaluation
of levels of ID and language (19, 33) in prior studies. The
group with seizures was also more likely to have more severe
behavioral problems, as measured by the ABCFX (Hyperactivity,
Irritability, and Stereotypy subscales). Availability of longitudinal
data allowed the delineation of key aspects in the evolution of
seizures in FXS and their association with other features of the
disorder. A longer course of epilepsy in FXS was associated with
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TABLE 4 | Comparison of characteristics between groups with no seizures, seizures reported for < 3 years, and seizures reported for > 3 years* .
Overall
(N = 659)
Variable

Number of evaluations

n

% or Mean
(SD)

659

Number of evaluations [Min, Max] 659

No Seizures
(N = 514)
n

% or Mean
(SD)

2.8 (2.0)

514

(1, 9)

514

Seizures < 3 years
(N = 70)
n

% or Mean
(SD)

2.8 (2.0)

70

(1, 9)

70

Seizures > 3 years
(N = 75)
n

% or Mean
(SD)

Overall

1 vs. 2

1 vs. 3

2 vs. 3

2.6 (1.7)

75

2.8 (2.1)

0.7533

0.4488

0.8982

0.6178

(1, 8)

75

(1, 8)
0.5789

0.8537

0.3185

0.3821

0.0535

0.0537

0.1033

0.7522

Number of evaluations–binary
1

235

35.7%

180

35.0%

24

34.3%

31

41.3%

2+

424

64.3%

334

65.0%

46

65.7%

44

58.7%

520

79.0%

395

77.0%

61

87.1%

64

85.3%

Gender
Male
Female

p-values

138

21.0%

118

23.0%

9

12.9%

11

14.7%

Age at first evaluation

659

19.9 (9.6)

514

21.1 (9.4)

70

14.7 (8.3)

75

16.4 (9.5)

<0.0001 <0.0001 <0.0001 0.2669

Age at last evaluation

659

22.6 (9.3)

514

23.8 (9.0)

70

17.6 (8.4)

75

18.9 (9.6)

<0.0001 <0.0001 <0.0001 0.3685

Years between first and last
evaluation

419

4.3 (2.2)

330

4.3 (2.3)

46

4.3 (2.1)

43

4.4 (2.2)

Age of onset

135

6.7 (6.6)

N/A

66

5.9 (5.3)

69

7.5 (7.6)

N/A

N/A

N/A

0.1625

Mean inter-evaluation period

423

1.8 (1.2)

333

1.8 (1.2)

46

2.0 (1.2)

44

1.6 (1.0)

0.3655

0.3427

0.3576

0.1326

Number of AEDs first evaluation

659

0.1 (0.5)

514

0.0 (0.0)

Number of AEDs first evaluation
[Median (IQR)]

659 0.0 (0.0-0.0)

Number of AEDs last evaluation

659

Number of AEDs last evaluation
[Median (IQR)]

659 0.0 (0.0-0.0)

0.2 (0.5)

514 0.0 (0.0-0.0)
514

0.0 (0.0)

514 0.0 (0.0-0.0)

0.9798

70

0.3 (0.5)

75

1.1 (1.0)

70

0.0 (0.0-0.0)

75

1.0 (0.0-2.0)

70

0.3 (0.5)

75

1.3 (1.0)

0.0 (0.0-0.0)

75

1.0 (1.0-2.0)

Generalized

61

45.5%

N/A

28

43.8%

33

47.1%

Partial

46

34.3%

N/A

16

25.0%

30

42.9%

Febrile

11

8.2%

N/A

10

15.6%

1

1.4%

Unknown

16

11.9%

N/A

10

15.6%

6

8.6%

Seizure type last seizure
evaluation
Generalized

39

45.9%

N/A

19

42.2%

20

50.0%

Partial

25

29.4%

N/A

10

22.2%

15

37.5%

Febrile

11

12.9%

N/A

10

22.2%

1

2.5%

Unknown

10

11.8%

N/A

6

13.3%

4

10.0%

Intellectual disability Dx last
evaluation
No ID

35

5.5%

31

6.3%

4

5.8%

0

0.0%

Delayed development

3

0.5%

0

0.0%

3

4.3%

0

0.0%

Borderline

35

5.5%

30

6.1%

2

2.9%

3

4.3%

Mild

146

23.0%

119

24.0%

11

15.9%

16

22.9%

Moderate

356

56.2%

274

55.4%

42

60.9%

40

57.1%

Severe

57

9.0%

40

8.1%

7

10.1%

10

14.3%

Profound

2

0.3%

1

0.2%

0

0.0%

1

1.4%

Language milestone (Q24) first
evaluation
Non-verbal

12

1.8%

6

1.2%

2

2.9%

4

5.3%

Signing

7

1.1%

5

1.0%

0

0.0%

2

2.7%

Babbling

2

0.3%

0

0.0%

1

1.4%

1

1.3%

Few words

52

8.0%

34

6.7%

7

10.1%

11

14.7%

Word combinations

64

9.9%

47

9.3%

9

13.0%

8

10.7%

Phrases

512

78.9%

413

81.8%

50

72.5%

49

65.3%

0.4309

0.4973

<0.0001 <0.0001 <0.0001 <0.0001

70

Seizure type first seizure
evaluation

0.8835

<0.0001 <0.0001 <0.0001 <0.0001

N/A

N/A

N/A

0.0051

N/A

N/A

N/A

0.0363

0.0001

0.0003

0.0735

0.1380

0.0049

0.0378

0.0004

0.6416

(Continued)
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TABLE 4 | Continued
Overall
(N = 659)
Variable

n

% or Mean
(SD)

No Seizures
(N = 514)
n

% or Mean
(SD)

Seizures < 3 years
(N = 70)
n

% or Mean
(SD)

Seizures > 3 years
(N = 75)
n

% or Mean
(SD)

Sustained conversation (Q26)
first evaluation
Non-verbal

26

4.1%

15

3.0%

4

6.0%

7

9.6%

Yes, sustained conversion

385

60.3%

320

64.1%

34

50.7%

31

42.5%

No sustained conversion

228

35.7%

164

32.9%

29

43.3%

35

47.9%

Language milestone (Q24) last
evaluation
Non-verbal

8

1.2%

5

1.0%

1

1.4%

2

2.7%

Signing

8

1.2%

5

1.0%

2

2.9%

1

1.3%

Babbling

4

0.6%

2

0.4%

0

0.0%

2

2.7%

Few words

40

6.1%

28

5.5%

1

1.4%

11

14.7%

Word combinations

53

8.1%

37

7.3%

10

14.3%

6

8.0%

Phrases

538

82.6%

429

84.8%

56

80.0%

53

70.7%

Sustained conversation (Q26)
last evaluation
Non-verbal

12

2.0%

9

1.9%

0

0.0%

3

4.5%

Yes, sustained conversion

404

65.8%

329

68.4%

41

62.1%

34

50.7%

No sustained conversion

198

32.2%

143

29.7%

25

37.9%

30

44.8%

No

321

48.9%

273

53.2%

20

28.6%

28

37.8%

Yes

328

49.9%

234

45.6%

48

68.6%

46

62.2%

Autism Dx ever

Autism Dx current (last
evaluation)
Yes

276

43.0%

196

39.0%

39

57.4%

41

57.7%

No

331

51.6%

277

55.1%

28

41.2%

26

36.6%

Don’t know

35

5.5%

30

6.0%

1

1.5%

4

5.6%

378

97.2%

295

98.0%

43

95.6%

40

93.0%

Sleep apnea last evaluation
No
Yes

p-values

Overall

1 vs. 2

1 vs. 3

2 vs. 3

0.0009

0.0774

0.0003

0.5314

0.0034

0.1536

0.0062

0.0358

0.0236

0.2432

0.0122

0.1287

0.0003

0.0005

0.0246

0.1952

0.0022

0.0095

0.0094

0.3945

0.1434

0.3075

0.0555

0.6080

<0.0001 <0.0001 0.0076

0.0795

11

2.8%

6

2.0%

2

4.4%

3

7.0%

ABC hyperactivity first evaluation

506

18.8 (7.4)

393

17.9 (6.9)

58

23.3 (8.1)

55

20.6 (8.0)

ABC inappropriate Speech first
evaluation

506

8.4 (3.4)

393

8.3 (3.4)

58

9.1 (3.6)

55

8.1 (3.3)

ABC irritability first evaluation

506

31.0 (11.9)

393

29.9 (11.4)

58

35.8 (14.1)

55

33.2 (11.8)

0.0006

0.0004

0.0473

0.2830

ABC social avoidance first
evaluation

506

7.7 (3.4)

393

7.7 (3.4)

58

7.6 (3.4)

55

7.4 (3.4)

0.7930

0.8768

0.4987

0.6881

ABC social unresponsiveness
first evaluation

506

18.8 (5.7)

393

18.5 (5.9)

58

19.9 (5.3)

55

19.6 (5.3)

0.1154

0.0811

0.1916

0.7393

ABC stereotypy first
evaluation

506

10.9 (4.8)

393

10.5 (4.6)

58

12.7 (5.4)

55

11.9 (5.1)

0.0011

0.0010

0.0296

0.4655

ABC hyperactivity last
evaluation

504

17.5 (6.9)

382

16.4 (6.2)

58

21.5 (7.2)

64

20.1 (8.3)

ABC inappropriate Speech last
evaluation

504

8.0 (3.4)

382

7.8 (3.4)

58

8.7 (3.5)

64

8.4 (3.4)

0.1310

0.0789

0.2204

0.6524

ABC irritability last evaluation

504

30.0 (11.7)

382

28.8 (11.1)

58

33.5 (12.3)

64

34.1 (13.0)

0.0002

0.0032

0.0007

0.8072

ABC social avoidance last
evaluation

504

7.5 (3.4)

382

7.4 (3.3)

58

8.1 (3.8)

64

7.2 (3.3)

0.2760

0.1532

0.6003

0.1568

ABC social unresponsiveness
last evaluation

504

18.4 (5.7)

382

18.2 (5.8)

58

19.0 (5.1)

64

19.5 (5.1)

0.1634

0.3221

0.0856

0.5669

ABC stereotypy last evaluation

504

10.5 (4.6)

382

10.1 (4.3)

58

11.8 (5.0)

64

12.0 (5.0)

0.0006

0.0061

0.0016

0.8347

0.2196

0.1187

0.5732

0.1172

<0.0001 <0.0001 <0.0001 0.3237

*for the p-values listed for group comparisons, 1 = no seizures, 2 = seizures for < 3 years, 3 = seizures for > 3 years.
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Strengths of this study are the size of the subject sample,
very large for rare disease standards, and the ability to examine
longitudinal data. Weaknesses include lack of availability of
follow-up visits into the late teenage years in about half the
cohort, lack of complete evaluations of seizure type (many were
undefined), and a relatively small population of adults in the
current FORWARD database. Additionally, as participants with
FXS were not a randomly selected, sampling biases inherent to
clinic-based samples cannot be discounted.
Based on the data from this study, the prototypical individual
with FXS and seizures would be male, with moderate or severe ID
and expressive language delay, with a DSM-5 diagnosis of ASD
and a corresponding SCQ >15 and SRS-2 in the severe range,
who had a first evaluation at a FORWARD (perhaps any FXS)
clinic after age 5. Females with FXS and seizures would show
similar characteristics; however, among females a subgroup with
a distinctive but uncommon profile of onset of seizures after age
15 is identified. It appears that this subgroup has greater cognitive
impairment than other females with or without seizures and had
a first evaluation at a FORWARD clinic after age 15. The duration
of seizures also seems to be a parameter associated with worse
outcomes, particularly in cognitive function.
FMRP has been linked to seizures in FXS through excessive
mGluR5 signaling of dendritic translation, based on reversal of
audiogenic seizures by mGluR5 blockers in the fmr1 knockout
mouse (48). FMRP also operates presynaptically and may cause
seizures through interruption of a direct interaction of FMRP
with a presynaptic BK channel subunit (49). Seizures are
associated with mutations in CYFIP2, which interacts with FMRP
(50), and FMRP appears to underlie enhanced mLTD in adult
rats triggered by early-life seizures (51). Thus, absence of FMRP
may potentiate seizure via multiple neural mechanisms which
are likely to vary between patients, thus resulting in variable
penetrance and severity of seizures in FXS. However, likely the
presence of seizures is a signal of more problematic neural and
synaptic dysfunction related to variation in FMRP deficits in
cells, and variation in these multiple interacting pathways. The
present study adds to the understanding of the characteristics,
risk factors, and course of seizures in FXS and provides a
basis for anticipatory guidance for clinicians and families. The
study also defines gaps and additional areas of investigation
that could answer further questions about seizures, their
neural underpinnings, and their evolution across the lifespan
in FXS.

of females with seizures in the cohort. Consequently, a larger
cohort would be needed to confirm that females with FXS have
a larger proportion of late-onset seizures than males. There is
a new concern in adolescents and adults with idiopathic ASD
of having new-onset seizures (43), especially in those with ID
(44), which appears to be linked to increased morbidity (45, 46).
Interestingly, we did not find this trend in those with FXS,
making this less of a concern in this genetic disorder.
As with idiopathic ASD and many other ID syndromes,
seizure type was variable between patients. However, the
proportions of generalized and partial seizures are in general
agreement with the literature (13–15, 19). Overall, the number
of anticonvulsants required for those with seizures was low,
consistent with past observations (15, 19). As might be
expected considering that males with FXS are more affected
than females, males with seizures were more likely to be on
anticonvulsants, including multiple drugs, and to be followed
in clinic and in FORWARD longer than females with seizures.
The anticonvulsants used in the FXS population were consistent
with recommendations in the field (2, 19, 47) and were those
typically employed in any pediatric seizure population, and
similar perhaps with somewhat less use of levetiracetam, most
likely due to concerns about aggravating behavior.
For all participants with follow-up visits in FORWARD,
new (i.e., incident) seizures were rare, with risk being only
approximately 1% per patient year of follow-up in FORWARD.
Risk of change in seizure type was only approximately 4% per
patient year. The Kaplan–Meier plot (Figure 4) shows risk of
having seizures at any given age across the lifespan. It is clear that
most seizures are present early in life. After being stable through
the 15–25 year age period with fewer patients having any seizure
during this time period, the proportion of seizures goes up after
age 25, most likely due to the small number of adults >25 years
old included in FORWARD to date. There is also a likely referral
bias such that patients are more likely to remain in care at an FXS
clinic if they have ongoing seizures or be referred to an FXS clinic
if they have new-onset seizures. This may be particularly the case
for clinics run by pediatric neurologists, who tend to see adults
with FXS more readily. Since the FORWARD project is now
focused on increasing enrollment of adults, it is expected that
more definitive estimates can be obtained for seizure prevalence
and onset in adults upon future analysis of a larger cohort.
When patients with longer duration of seizures (>3 years)
were compared with those with shorter duration (<3 years),
only a few differences emerged, including increased use of
anticonvulsants, higher prevalence of partial seizures, and lower
prevalence of febrile seizures and, most importantly, more severe
language outcomes despite lack of differences in behavioral
abnormalities (including ASD) and non-significant increases in
ID severity. This suggests that a longer course of seizures in FXS
is an index of severity linked to more severe outcome in this some
functional domains. It is possible that the division of the groups
at 3 years of persistent seizures did not isolate those with the most
severe phenotypes and a 5 year cutoff might have been better
to more fully explore this concept. Nonetheless, there were not
enough patients in FORWARD with 5 years of longitudinal data
at present to support such an analysis.
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